Company intelligence / Profile preview

ZBiotics

San Francisco, California, United States

Ownership: Private
Employees: ~46
Development stage: Other

Overview

ZBiotics' flagship probiotic beverage, engineered to break down acetaldehyde, has been commercially successful with over 5 million units sold and company-wide profitability reached in 2023; new products for gut health, sleep, vaginal health, and athletic performance are under R&D.

Therapeutic areas: Women's HealthGastroenterologyNeurologyOther
Modalities: Live biotherapeutic product therapyMicrobial therapyGenetically engineered probiotic
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on ZBiotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZBiotics.

Explore the full profile